Deutsche Bank AG reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Wednesday. They currently have a GBX 5,800 ($75.71) price target on the biopharmaceutical company’s stock.
AZN has been the subject of several other research reports. Berenberg Bank set a GBX 5,550 ($72.44) target price on shares of AstraZeneca plc and gave the stock a buy rating in a research note on Thursday, August 25th. HSBC reiterated a hold rating and issued a GBX 4,240 ($55.35) price objective on shares of AstraZeneca plc in a research note on Friday, June 17th. Citigroup Inc. restated a buy rating on shares of AstraZeneca plc in a report on Wednesday, July 27th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc and gave the company a sell rating in a report on Wednesday, August 10th. Finally, Bryan, Garnier & Co restated a buy rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded down 0.30% during trading on Wednesday, reaching GBX 5027.00. 851,968 shares of the company’s stock traded hands. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s market capitalization is GBX 63.59 billion. The firm has a 50 day moving average of GBX 5,006.61 and a 200 day moving average of GBX 4,427.08.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. This represents a yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.